Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Mozobil Generic Name & Formulations
Legal Class
Rx
General Description
Plerixafor 20mg/mL; soln for SC inj; preservative-free.
Pharmacological Class
Hematopoietic stem cell mobilizer.
How Supplied
Single-dose vial (1.2mL)—1
Manufacturer
Generic Availability
NO
Mozobil Indications
Indications
In combination with granulocyte colony stimulating factor (G-CSF): To mobilize hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.
Mozobil Dosage and Administration
Adult
Start after 4 days' treatment with G-CSF. Give by SC inj approx.11hrs before starting apheresis. Repeat up to 4 consecutive days. Base dose on actual body weight. ≤83kg: 20mg fixed dose or 0.24mg/kg once daily; >83kg: 0.24mg/kg once daily. Max 40mg/day. Renal impairment (CrCl≤50mL/min): ≤83kg: 13mg or 0.16mg/kg once daily; >83–<160kg: 0.16mg/kg once daily; max 27mg/day.
Children
Not established.
Mozobil Contraindications
Not Applicable
Mozobil Boxed Warnings
Not Applicable
Mozobil Warnings/Precautions
Warnings/Precautions
Not for use in leukemia. May cause mobilization of tumor cells (in combination with G-CSF). Monitor blood and platelet counts. Monitor for splenic enlargement/rupture after administration in combination with G-CSF; evaluate if left upper abdominal pain and/or scapular or shoulder pain occurs. Monitor for signs/symptoms of hypersensitivity during and after administration for at least 30mins. Have anaphylactic treatment readily available. Moderate to severe renal impairment. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 1 week after last dose. Pregnancy: avoid; exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after last dose).
Mozobil Pharmacokinetics
See Literature
Mozobil Interactions
Interactions
May be potentiated by drugs that reduce renal function or compete for active tubular secretion.
Mozobil Adverse Reactions
Adverse Reactions
Diarrhea, nausea, fatigue, inj site reactions, headache, arthralgia, dizziness, vomiting; hypersensitivity reactions (may be serious), tumor cell mobilization, leukocytosis, thrombocytopenia, enlarged spleen, vasovagal reaction may occur.
Mozobil Clinical Trials
See Literature
Mozobil Note
Not Applicable
Mozobil Patient Counseling
See Literature
Images
